Patient Preferences For Chemotherapy In The Treatment Of Non-Small Cell Lung Cancer: A Multicenter Discrete Choice Experiment (DCE) Study In China
Open Access
- 1 October 2019
- journal article
- research article
- Published by Taylor & Francis Ltd in Patient Preference and Adherence
- Vol. ume 13, 1701-1709
- https://doi.org/10.2147/ppa.s224529
Abstract
Objective: The study aims to quantify patients’ risk-benefit preferences for chemotherapy in the treatment of non-small cell lung cancer (NSCLC), and to elicit their willingness to pay (WTP) for treatment outcomes. Methods: A face-to-face discrete choice experiment (DCE) was conducted on NSCLC patients in four tertiary hospitals each from Beijing, Shanghai, Guangzhou and Chengdu in China. Patients were invited to complete choice questions that constructed by seven attributes: progression-free survival (PFS), disease control rate (DCR), rash, nausea and vomiting, tiredness, mode of administration and out-of-pocket costs. A mixed logit model was used to evaluate the choice model. Estimates of relative preferences and marginal willingness to pay for each attribute were then explored. Results: A total of 361 patients completed the survey. Improvements in PFS (10, 95% CI: 8.4–11.6) were the most important attribute for patients, followed by increase in DCR (4.6, 95% CI: 3.4–5.8). Tiredness (3.9, 95% CI: 2.9–5.1) was judged to be the most important risk. While remaining attributes were ranked in decreasing order of importance: nausea and vomiting (1.9, 95% CI: 0.9–3.0), mode of administration (0.8, 95% CI: 0.2–1.4) and rash (0.5, 95% CI: −0.6–1.5). There was little variation in preferences among patients with different sociodemographic characteristics. Patients were monthly willing to pay $2304 (95% CI, $1916–$2754) that guaranteed 11 months of PFS, followed by $1465 (95% CI, $1163-$1767) per month to improve their disease control rate by 90%. Conclusion: The results suggested that efficacy was the most important attribute for patients. Side effects, mode of administration and treatment cost significantly influenced patient preferences. Patient engagement in prioritizing their treatment preferences should be emphasized during the clinical decision-making process and regimen implementation.Keywords
This publication has 42 references indexed in Scilit:
- Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trialThe Lancet Oncology, 2013
- Shared Decision MakingCirculation: Cardiovascular Quality and Outcomes, 2012
- Patients’ preferences for chemotherapy in non-small-cell lung cancer: A systematic reviewLung Cancer, 2010
- Patient willingness to undergo chemotherapy and thoracic radiotherapy for locally advanced non‐small cell lung cancerPsycho‐Oncology, 2008
- Systemic Chemotherapy for Advanced Non‐Small Cell Lung Cancer: Recent Advances and Future DirectionsThe Oncologist, 2008
- Conducting Discrete Choice Experiments to Inform Healthcare Decision MakingPharmacoEconomics, 2008
- Patient-based health technology assessment: A vision of the futureInternational Journal of Technology Assessment in Health Care, 2007
- Effects coding in discrete choice experimentsHealth Economics, 2005
- Do patients benefit from participating in medical decision making? Longitudinal follow-up of women with breast cancerPsycho‐Oncology, 2005
- Patient Preferences for Medical Decision MakingMedical Care, 2000